MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$26,661K
Free Cash flow
-$14,577K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of marketable securit...
    • Accrued expenses
    • Stock-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Net loss
    • Accretion of discounts on market...
    • Non-cash lease income
Cash Flow
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Net loss
-18,086
41,667
-21,059
-38,646
Stock-based compensation expense
1,543
-3,167
1,383
3,176
Depreciation
24
-66
31
69
Accretion of discounts on marketable securities
382
-1,873
694
1,564
Non-cash lease income
3
-5
3
4
Gain on termination of lease, net
0
24
-
-
Loss on sales and disposals of fixed assets, net
-25
37
1
-38
Other, net
0
-16
-1
16
Prepaid expenses and other assets
-253
2,952
162
-3,167
Operating lease right-of-use assets and liabilities
0
-
-
-
Accounts payable
389
1,656
801
-3,981
Accrued expenses
1,660
-2,262
-117
1,193
Net cash used in operating activities
-14,577
36,709
-19,820
-36,568
Purchases of property and equipment
0
-14
-1
15
Proceeds from sale of property and equipment
-31
-
1
30
Purchases of marketable securities
26,728
-56,486
20,473
46,689
Maturities of marketable securities
14,501
-87,373
32,499
86,374
Net cash provided by investing activities
-12,227
-30,904
12,028
39,700
Proceeds from the exercise of stock options
-
0
-
-
Proceeds from the exercise of stock options and common stock issued under the 2020 plan
30
-
0
113
Net cash provided by financing activities
143
-113
0
113
Impact of exchange rates on cash and cash equivalents
0
-6
2
6
Net (decrease) increase in cash and cash equivalents
-26,661
5,686
-7,790
3,251
Cash and cash equivalents - beginning of period
36,337
36,337
40,876
-
Cash and cash equivalents - end of period
12,469
39,130
36,337
-
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

something is missing$113K Proceeds from theexercise of stock options...$30K (-73.45%↓ Y/Y)Net cash provided byfinancing activities$143K (26.55%↑ Y/Y)Net (decrease)increase in cash and cash...-$26,661K (-920.09%↓ Y/Y)Canceled cashflow$143K Accrued expenses$1,660K (39.15%↑ Y/Y)Stock-based compensationexpense$1,543K (-51.42%↓ Y/Y)Accounts payable$389K (109.77%↑ Y/Y)Prepaid expenses andother assets-$253K (92.01%↑ Y/Y)Loss on sales anddisposals of fixed assets,...-$25K (34.21%↑ Y/Y)Depreciation$24K (-65.22%↓ Y/Y)Maturities of marketablesecurities$14,501K (-83.21%↓ Y/Y)Net cash used inoperating activities-$14,577K (60.14%↑ Y/Y)Net cash provided byinvesting activities-$12,227K (-130.80%↓ Y/Y)Canceled cashflow$3,894K Canceled cashflow$14,501K Net loss-$18,086K (53.20%↑ Y/Y)Purchases of marketablesecurities$26,728K (-42.75%↓ Y/Y)Accretion of discounts onmarketable securities$382K (-75.58%↓ Y/Y)Non-cash lease income$3K (-25.00%↓ Y/Y)

PMV Pharmaceuticals, Inc. (PMVP)

PMV Pharmaceuticals, Inc. (PMVP)